Perusing Progress Made in NSCLC in Washington DC

Recently, we headed to Washington D.C. for a State of the Science Summit on Non–Small Cell Lung Cancer. Topics ranged from determining optimal strategies for molecular interrogation in NSCLC to the emergence of rare, targetable biomarkers—such as MET, RET, and NTRK. Presentations also focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.